Webcast

If this is your first time accessing any of the Presentations from JADPRO Live at APSHO 2016, please take a moment to create an account using the Register link to the right. Otherwise, please log in with your username and password to proceed. Please contact ce@annenberg.net with any questions.

A continuing education activity for physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists.

This activity is supported by an independent medical educational grant from Sandoz Inc., a Novartis Company.

Release date: January 17, 2017                    Estimated time to complete activity: 0.75 hours
Expiration date: January 17, 2018

Faculty

James S. Lewis II, PharmD, FIDSA
Oregon Health & Science University

Activity Rationale and Purpose
Treatment-induced infections add to the risk of mortality in patients with cancer. Colony-stimulating factors (CSFs) have been used in oncology patients at risk for neutropenia with the goal of decreasing hospitalizations, the need for intravenous anti-infectives, and mortality. In order to identify patients who will benefit from prophylactic CSF, the individual patient’s risk factors related to developing febrile neutropenia must be determined. Once a patient is identified as needing CSF, the advanced practitioner (AP) needs a strong understanding of which agent is most appropriate for the individual patient and whether or not a biosimilar product can be used as part of the armamentarium against febrile neutropenia and infection.

Intended Audience
The intended audience for this enduring internet activity is physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists who specialize in the field of oncology.

Learning Objectives
After completing this educational activity, participants should be able to:

  • Identify risk factors for febrile or prolonged neutropenia and the potential clinical outcomes of these conditions in oncology patients
  • Assess the role and interchangeability of biosimilar and reference biologic G-CSFs in the prophylaxis and treatment of FN
  • Understand the impact of worrisome developments with respect to superinfection and drug resistance
  • Describe treatments for infections commonly seen in patients with cancer, as well as what advanced practitioners should be aware of when strategizing a treatment approach

Continuing Education

Physicians

Annenberg Center for Health Sciences at Eisenhower

The Annenberg Center for Health Sciences at Eisenhower has been awarded Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME®)

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

A maximum of 0.75 contact hours may be earned for successful completion of this activity.

Pharmacists

Accreditation Council for Pharmacy Education

This knowledge-based accredited education lecture is intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Annenberg Center for Health Sciences at Eisenhower.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program
# 0797-9999-17-002-H04-P. This program is designated for up to 0.75 contact hours (0.075 CEUs) of continuing pharmacy educational credit.

Financial Disclosures
All individuals in positions to control the content of this activity (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

Faculty
James S. Lewis II, PharmD, FIDSA has served as a consultant for Accelerate Diagnostics, Achaogen, Astellas, Cempra, Medicines Company, Merck, Paratek, and Seres Therapeutics.

Lead Nurse Planner
Wendy J. Smith ACNP, AOCN®, has nothing to disclose.

Planners
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CS, ANP, has nothing to disclose.
Lynn Rubin has nothing to disclose.
Annie Yueh has nothing to disclose.

Content Reviews
Wendy J. Smith ACNP, AOCN®, has nothing to disclose.

Annenberg Center for Health Sciences at Eisenhower
The staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclaimer
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of the Annenberg Center for Health Sciences, Meniscus Educational Institute and JADPRO for all educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Meniscus Educational Institute of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

How to Earn Credit
To access the learning assessment and evaluation form online, visit education.annenberg.net/jpl16-sessions.

Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment and complete and submit the evaluation form) will be able to download a statement of credit.

Course summary
Available credit: 
  • 0.75 ACPE
  • 0.75 AMA PRA Category 1 Credit(s)™
  • 0.75 Attendance
  • 0.75 ANCC
Course opens: 
01/05/2017
Course expires: 
01/17/2018
Cost:
$0.00
Rating: 
0

Available Credit

  • 0.75 ACPE
  • 0.75 AMA PRA Category 1 Credit(s)™
  • 0.75 Attendance
  • 0.75 ANCC

Accreditation Period

Course opens: 
01/05/2017
Course expires: 
01/17/2018

Price

Cost:
$0.00
Please login or register to take this course.